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Abstract
Background: Signaling via protein lysine methylation has been proposed to play a central role in the regulation of
many physiologic and pathologic programs. In contrast to other post-translational modifications such as
phosphorylation, proteome-wide approaches to investigate lysine methylation networks do not exist.
Results: In the current study, we used the ProtoArray
® platform, containing over 9,500 human proteins, and
developed and optimized a system for proteome-wide identification of novel methylation events catalyzed by the
protein lysine methyltransferase (PKMT) SETD6. This enzyme had previously been shown to methylate the
transcription factor RelA, but it was not known whether SETD6 had other substrates. By using two independent
detection approaches, we identified novel candidate substrates for SETD6, and verified that all targets tested in
vitro and in cells were genuine substrates.
Conclusions: We describe a novel proteome-wide methodology for the identification of new PKMT substrates. This
technological advance may lead to a better understanding of the enzymatic activity and substrate specificity of the
large number (more than 50) PKMTs present in the human proteome, most of which are uncharacterized.
Background
Lysine methylation of proteins plays a key role in many
signaling and biological pathways, and disruption of this
modification can lead to the development of disease [1,2].
A lysine residue in a given protein can be monomethy-
lated, dimethylated or trimethylated by protein lysine
methyltransferases (PKMTs). There are approximately 50
PKMTs known to be present in the human proteome, but
the enzymatic activity and substrate specificity of most of
them are not known. Despite the importance of lysine
methylation in maintaining cellular homeostasis, the
development of proteome-wide approaches for detecting
this modification has been limited and has proven techni-
cally difficult. Most methods aimed at identifying new
PKMT substrates use candidate-based or mass-spectrome-
try approaches [3,4]. Peptide-array technologies are also
used to identify new targets and potential consensus
sequences for a given PKMT [5,6].
In the current study, we used a human protein microar-
ray-based platform (ProtoArray
®; Invitrogen Corp., Carls-
bad, CA, USA) to identify new substrates for PKMTs. This
system contains more than 9,500 highly purified recombi-
nant human proteins, expressed in insect cells as N-term-
inal glutathione S-transferase (GST) fusion proteins, which
are immobilized at spatially addressable positions on nitro-
cellulose-coated glass microscope slides. This proteomic
platform has been successfully used for identification of
new substrates for protein kinases and ubiquitin ligases,
novel NEDDylation and SUMOylation targets, and pro-
tein-protein interactions [7-10], providing important
insights into numerous biological pathways.
As a proof of principle, we first used the protein array
system to validate known substrates for the well-defined
PKMT enzyme SETD7 [11-13]. We then identified novel
candidate substrates for SETD6, a mono-methyltransferase
w i t has i n g l er e p o r t e ds u b s t r a te, the transcription factor
RelA [14]. Finally, to test the reliability of the system, we
cloned six candidate SETD6 substrates, and found that all
of them were methylated by SETD6 in vitro. Out of these
six, two that were tested were also methylated in cells.
Together, this system represents a powerful tool for the
identification of novel PKMT substrates, which should
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Results
Methodology
To identify new substrates of PKMTs, we performed a
proteomic screen using protein arrays containing more
than 9,500 recombinant human proteins spotted in
duplicate on a glass slide (Figure 1). Protein microarrays
were blocked with 1% BSA before being subjected to
on-chip methyltransferase assays with a purified recom-
binant PKMT or with GST as a negative control, in the
presence of S-adenosyl methionine (SAM), a PKMT co-
factor that donates a methyl group to the substrate dur-
ing the methyltransferase reaction. Fluorescence-based
and radioactive-based detection approaches were used
to independently identify methylation events and hence
putative PKMT substrates.
In the fluorescence method, after an on-chip methyl-
transferase reaction, the arrays were first probed with a
pan-methyl antibody that recognizes monomethylated
lysine residues, and then incubated with a fluorophore-
conjugated secondary antibody (Alexa Fluor 647) that pro-
duces a fluorescent signal. In the radioactive detection
Figure 1 Protein lysine methyltransferase (PKMT) ProtoArray
® system. A schematic of the experimental procedures used to identify new
PKMT substrates using both the fluorescence and the radioactive detection methods.
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during the PKMT reaction. After incubation, arrays were
exposed to radiographic film, which was then scanned and
analyzed. The specificity of the enzymatic reaction was
determined by comparing the signal obtained with recom-
binant PKMTs with the GST control reaction (see Meth-
ods section, under ‘Data analysis’,f o rm o r ed e t a i l s ) .
Multiple controls were printed on each protein array chip
to evaluate detection conditions and background signal
(Additional file 1, Figure S1). For the fluorescent detection
method, IgG and biotin antibodies (along with an Alexa
Fluor antibody) served as positive controls for fluorescence
scanning and for orientation of the microarray image (see
Additional file 1, Figure S1A). For the radioactivity
method, tritium-labeled estradiol, which specifically binds
to the estrogen receptor (ER)-a, which was printed on the
array, was added to the reaction and used as an array
image orientation signal (see Additional file 1, Figure S1B).
Characterization of pan-methyl epitope specificities
The identification of new PKMT substrates in the fluores-
cence detection method was achieved using a pan-methyl
antibody that specifically recognizes methylated lysine resi-
dues. Although many such commercial antibodies are
available, they vary widely in epitope specificity. Therefore,
we first characterized the specificity of three such antibo-
dies using a human epigenome peptide microarray plat-
form (HEMP) (Figure 2) [15]. In this procedure, more than
120 unique biotinylated modified or unmodified 21-mer
peptides were spotted onto streptavidin-coated slides
(Figure 2A) [15]. Arrays were then probed with three dif-
ferent pan-methyl antibodies, which yielded considerably
differing patterns of detected methylation (Figure 2). The
pan-methyl me1/me2 antibody (PA000588-P0501; Syd
Labs, Inc. Malden, MA, USA) detected methylated peptides
but also crossreacted with phosphorylated, acetylated and
citrullinated epitopes (Figure 2B). A second pan-methyl
antibody (ab23366/904302; Abcam, Cambridge, Cambrid-
geshire, UK) exhibited methylation-specific reactivity, but
recognized only trimethylated peptides (Figure 2C). Rela-
tive to the first two antibodies tested, the third antibody
(23366/915620; Abcam) was highly specific to monomethy-
lated and trimethylated peptides, and did not crossreact
with unmethylated peptides on the array (Figure 2D).
Therefore, we chose to use this antibody for the fluores-
cence detection method.
Calibration and initial testing of the protein array system
for identifying PKMT substrates
To define a positive hit and to reduce the likelihood of
false positives, we filtered candidate substrates using a
signal-to-noise (SNR) threshold method (Figure 3A). The
SNR value is defined as the ratio of the background-sub-
tracted mean signal intensity at 635 nm to the standard
deviation of the mean background intensity. We then
applied the following stringent filtering method to deter-
mine potential candidates (Figure 3A): 1) the average
SNR value for each duplicate protein feature printed on
an array (approximately 9,500 proteins in total) was cal-
culated based on two independent arrays for each PKMT
and three for GST; 2) only substrates with PKMT SNR ≥
3a n dG S TS N R≤ 3 were considered for further analysis;
and 3) an SNR difference of ≥ 3 between the PKMT and
the GST was required in order for it to be defined as a
positive hit (Figure 3A).
We derived the SNR threshold of 3 empirically, by using
intra-array concordance (see Additional file 2, Figures S2A
and B) from pairs of replicate spots on individual microar-
rays (r > 0.97, P < 0.0001) and inter-array concordance of
replicate measurements from pairs of replicate microarrays
(see Additional file 2, Figures S2C and D). Our choice of
SNR threshold was an attempt to balance the generally
high concordance (r >0 . 8 5 ,P < 0.0001) of signal measured
for the same protein across replicate microarrays against
the number of features preserved at a given SNR threshold
(see Additional file 2, Figure S2C).
Because the mono-methyltransferase SETD7 has been
reported to methylate numerous substrates [11,12], we
first sought to examine the feasibility of the protein array
system by testing the activity of SETD7. To this end,
arrays were incubated overnight with recombinant SETD7
or with GST as a negative control, probed with the pan-
methyl antibody, and scanned for analysis. In total, the
arrays yielded 321 positive candidates (Figure 3B), includ-
ing histone H3, histone H2A and histone H2B, which have
been previously reported to be SETD7 substrates [11,13],
and are printed on the arrays. Using Gene Ontology (GO;
http://geneontology.org) annotations, we analyzed positive
candidates for localization patterns. Of the substrates with
localization data, 19% were found in the nuclear fraction,
52% in the extranuclear fraction, and 29% in both fractions
(see Additional file 3, Figure S3A, B; see Additional file 4),
a finding that agrees with previous work showing nuclear
and cytosolic localization of SETD7 [16]. Also consistent
with our data, approximately 100 proteins with previously
validated SETD7 methylation sites [11] were found to
have diverse nuclear and/or extranuclear localization pat-
terns (see Additional file 3, Figure S3A). These results sug-
gest that this protein array system is a robust platform for
performing PKMT reactions in a proteome-wide manner.
Identification and validation of new SETD6 candidate
substrates
We have recently reported that SETD6 mono-methylates
RelA on lysine 310, leading to repression of RelA target
genes [14,17]. Because RelA is the only SETD6 substrate
known to date, we used the protein array to identify addi-
tional substrates of SETD6. In total, 118 hits passed the
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date substrates (Figure 3C; see Additional file 5 for sub-
strate list). The RelA protein printed on the array was not
detected because it included only amino acid residues 1 to
221, and is lacking the SETD6 methylation site at lysine
310.
Figure 2 Characterization of a-pan-methyl antibody specificities. (A) A diagram of the peptides present on the arrays and spatial addresses
of immobilized peptides. (B-D) A peptide microarray containing the indicated peptides in (A) was probed with (B) a-pan-methyl me1/me2
(PA000588-P0501, Syd Labs) (C) a-pan-methyl me1/me2 ab23366/904302 and (D) a-pan-methyl me1/me2 ab23366/915620.
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diagram of the procedure used to define a positive hit. See text for detailed description. (B, C) ProtoArrays
® were incubated with (B) SET
domain-containing SETD7 and (C) SETD6 in PKMT reaction buffer overnight at 30°C, probed with a pan-methyl antibody, then followed by
washes and incubation with an Alexa Fluor 647 secondary antibody. Arrays were then scanned (Axon Genepix 4000B; Molecular Devices) and
analyzed using Genepix 6.1 software. Representative magnified block images from a full ProtoArray
® slide are shown for SETD6, SETD7, and
glutathione S-transferase (GST; negative control). The enlarged region shows specific examples of substrate methylation by the different
enzymes, and their relative location on the arrays. Graphs below images show the calculated signal-to-noise ratio (SNR) for individual substrates
of each enzyme (red; 321 substrates for SETD7 and 118 for SETD6), compared with GST (blue). SNR was calculated based on three independent
experiments for GST and two independent experiments for both SETD7 and SETD6. SD, standard deviation.
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approach as an independent detection method. Consis-
tent with the fluorescent detection approach and a pre-
vious report [11], histones H2A and H2B were again
identified as SETD7 substrates (data not shown). Next,
we used this method to screen for SETD6 substrates
(Figure 4A). The arrays incubated with GST as a nega-
tive control produced few hits, most of which were pro-
teins with intrinsic methyltransferase activity. By
contrast, 114 candidates substrates were identified in the
arrays methylated with SETD6 (Figure 4A; see Addi-
tional file 5 for substrate list).
Next, positive SETD6 hits from both detection methods
were classified into three groups (Figure 4B). Group A (92
proteins) comprised substrates that were found only with
the fluorescent detection method and were not found
using the radioactive method; group B (88 proteins) were
substrates that were found only with the radioactive
method and not with the fluorescent approach; and group
AB (26 proteins) were the substrates detected by both
methods, with a significant overlap (P=2.24 × 10
26).
Functional enrichment analysis [18] applied to the union
of groups A and B showed significant enrichment in gen-
eral RNA-processing and RNA/DNA-binding functions,
and enhanced localization to subnuclear regions and ribo-
nucleoprotein components (P < 0.05). Moreover, distinct
gene sets originating from each group generally mapped
to the same enriched biological term, further confirming
the utility of our two-assay approach to detect function-
ally-related PKMT candidate substrates (see Additional
file 6 and Additional file 7 for the GO analysis gene list).
We also analyzed groups A and B specifically for protein
localization and compared them with SETD7 substrates
(see Additional file 3, Figure S3A, B). We found that a lar-
ger fraction of candidate SETD6 substrates are localized to
the nucleus (see Additional file 3, Figure S3A, C; see Addi-
tional file 4), and a larger proportion of proteins ‘shuttle’
between nuclear and extranuclear regions (see Additional
file 3, Figure S3C). Notably, such shuttling was also seen
for the genuine SETD6 substrate, RelA [14].
We selected six candidate substrates for direct valida-
tion: two from group A, one from group B and three from
group AB (Figure 4C, D). The full-length sequences of the
six candidates were cloned and the purified proteins (see
Additional file 8, Figure S5) were used in direct in vitro
methylation assays with recombinant SETD6. We found
that SETD6 methylates all six proteins, but not GST
(Figure 4D). The fact that substrates from each of the
three groups (A, B AB) are genuine, in vitro SETD6 sub-
strates indicates that the two detection methods are com-
plementary and thus both can be used to screen for new
PKMT substrates. To further investigate whether these
substrates can be methylated in cells, PLK1 and PAK4
were overexpressed in 293T cells with or without SETD6,
followed by immunoprecipitation and western blot analyis
with the same pan-methyl antibody used in the fluores-
cence detection method; both substrates were found to be
physiological substrates of SETD6 (Figure 4E).
Discussion
Post-translational modifications such as phosphoryla-
tion, acetylation and methylation are central to many
biological processes. The ProtoArray
® platform has been
used previously to characterize the enzymatic activity of
enzymes such as kinases and ubiquitin ligases [8,9].
However, similar approaches for profiling PKMT activity
on a proteome-wide scale have not been described. The
protein arrays described here serve as a powerful tool to
investigate the specificity of PKMTs, because they allow
screening of more than 9,500 different substrates in a
single experiment. In this study, we used the protein
array platform and developed two independent screen-
ing methods for the identification of new substrates of
PKMTs.
Each of the two detection methods used in the study
has certain advantages, but also has limitations on sensi-
tivity, and this motivated the complementary approach
that we used. Antibody specificity is a crucial parameter
for the success of the fluorescent detection method. As
many commercially available pan-methyl antibodies
crossreact with unmodified or non-methyl-modified
sequences, we used the HEMP platform [15] to carefully
characterize the antibody that was used for the protein
array experiments. Although the antibody we used did
not crossreact with unmethylated peptides, it also failed
to detect all methylated peptides (Figure 2D). Thus,
detection with the pan-methyl antibody probably missed
a subset of biologically important targets. Improved
methyl-specific antibodies should overcome this limita-
tion in the future. In using GST as a negative control in
these experiments, incorporating it in the substrate-can-
didate filtering method (Figure 3A), we increased the
reliability of the results by eliminating potential targets
that crossreact with the pan-methyl antibody in a
PKMT-independent manner. Furthermore, using an
antibody as a detection method makes the procedure
fast, inexpensive and convenient.
We also used a second detection method with radioac-
tively labeled SAM to screen the protein array for new
PKMT substrates. Radioactively labeled SAM has been
successfully used for in vitro PKMT assays in candidate-
based approaches, and has led to the characterization of
the activity of novel PKMTs and the identification of new
methylated substrates, mainly histones [3,14,19,20]. One
of the main advantages of this radiolabeled SAM detec-
tion method is that it exhibits very low background signal
when incubated with GST, making it a very sensitive
method for detection and identification of methylation
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® were incubated with SETD6 (left) or glutathione S-transferase (GST) (right) in
protein lysine methyltransferase (PKMT) reaction buffer + radiolabeled S-adenosyl methionine (SAM) overnight on a rocking platform. Scanned
film was analyzed with Genepix 6.1 software. Representative magnified block images from a full ProtoArray
® slide are shown for SETD6 and GST
as in Figure 3B, C. (B) Venn diagram of the identified SETD6 substrates found only by fluorescence detection (group A), only by radioactivity
detection (group B), and by both detection methods (group AB). The significance (P-value) of overlap for group AB was calculated using the
hypergeometric distribution with a population size of 9,480 (the number of non-control proteins printed on the array). (C) Magnified ProtoArray
®
images of the six SETD6 candidate substrates chosen for the validation experiments. F, fluorescent-labeled SAM, R, radioactive-labeled SAM.
Brackets represent the different groups defined in (B). (D) Autoradiograph of the indicated GST-tagged purified proteins that were used in the in
vitro methylation assay with recombinant SETD6 followed by SDS-PAGE. The location of each protein is indicated by an asterisk. Molecular size
(kDa) is shown. (E) Western blot analysis of Flag immunoprecipitations or whole-cell extracts (WCE; 2% of total) from 293T cells transfected with
the indicated plasmids. f, Flag. Molecular size (kDa) is shown.
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Furthermore, in detecting new methylation events, it
does not rely on new methylation events being recog-
nized by existing antibodies. However, under our current
conditions, this radioactivity assay has limitations in its
sensitivity relating to the activity of the methyltransferase
and the amount of
3H-methyl donor from SAM (used at
a much lower stoichiometric ratio), as well as the inher-
ent limitations of signal and background in the detection
and imaging of radioactivity exposed on film.
Despite these limitations, the overlap between the meth-
ods was highly significant, supporting reproducible enrich-
ment of targets of such modification as detected by both
methods (Figure 4B). Further, although each assay did
indeed identify distinct candidates, all of the six candidate
targets tested, including all three of those detected by one
(but not both) of the two methods, were experimentally
validated (Figure 4D). Accordingly, this observation sug-
gests that each of these two complementary methods has
a different sensitivity profile, allowing identification of dis-
tinct groups of proteins that are targets of methyltrans-
ferases and that are experimentally intractable by the
alternative method. Moreover, when considering the
union of PKMT targets identified by both methods, signifi-
cant enrichment was seen for proteins with common sub-
cellular localization, molecular functions and roles in
biological processes (see Additional file 3, Figure S3; see
Additional file 6, Figure S4), consistent with our findings.
Thus, these two methods exhibit both overlapping and
complementary detection of candidate methyltransferase
protein substrates.
Despite the strength of this protein array system as a
proteomic platform, there are still several limitations that
have to be taken into account when using this system.
First, the latest generation protein microarrays used here
(version 5.0) contain approximately 9,500 immobilized
human proteins, representing only around on-third of the
proteome. In many cases, proteins that were reported to
be a target for a specific PKMT were not present on the
array, including, p53 [16], DNMT1 [21] and TAF10 [22],
which have all reported to be methylated by SETD7. Cus-
tom arrays have been previously used for global analysis of
protein phosphorylation in yeast [23,24]; however, the
yeast proteome is significantly smaller than the human
proteome, and an array displaying the entire human pro-
teome is not currently available. Second, for many proteins
on the protein array used, the spotted protein does not
cover the full-length sequence, so some positive hits may
be missed. For example, we recently found that SETD6
methylates RelA on lysine 310 [14,17]; although the array
does contain RelA, the sequence covers only amino acids
1t o2 2 1 ,a n dl a c k sl y s i n e3 1 0 .T h i r d ,i ns o m ec a s e s ,t h e
signal intensity for a specific known substrate on the array
was not strong enough to pass the stringent threshold we
used in order to reduce the number of false positives.
Finally, it is likely that subsets of recombinant proteins are
poor in vitro substrates for PKMTs because they are not
properly folded, or are lacking crucial cofactors as part of
larger macromolecular complexes.
In total, we identified 118 and 114 SETD6 new candi-
date substrates using the fluorescent and the radioactive
detection methods respectively, and all six that were
tested from both methods were confirmed to be genuine
in vitro substrates. Two serine/threonine kinases were
discovered: PAK4 regulates cytoskeletal architecture, cell
proliferation, and the cell cycle, and is required for
embryonic viability [25,26], while PLK1 is involved in
regulation of mitosis, including centrosome maturation
and spindle assembly [27].
We also validated the methylation of the ribosomal pro-
tein RPS27L by SETD6; RPS27L is overexpressed in multi-
ple human cancers, including colon [28], prostate [29],
breast [30], liver [31], and head and neck carcinomas [32],
and was recently shown to be a p53 target gene that regu-
lates p53 protein levels [33]. We found that SETD6 methy-
lates two splicing factors, DNAJC8 and SRSF2. Although
the function of DNAJC8 is still unknown, SRSF2 has been
identified as a serine/arginine-rich protein belonging to
the family of SR proteins that are crucial regulators of con-
stitutive and alternative pre-mRNA splicing, and is also
involved in regulating apoptosis in response to genotoxic
stress [34]. Finally, as a substrate for SETD6, we also iden-
tified the elongation factor transcription elongation factor
A protein 1 (TCEA1) which is necessary for efficient RNA
polymerase II transcriptional elongation [35]. Together,
these six proteins are involved in diverse biological
processes, and future work is needed to elucidate the
mechanistic and biological consequences of these SETD6-
mediated methylation events.
Conclusion
We describe here a novel proteome-wide approach for the
identification of new PKMT substrates. Integration of the
ProtoArray
® data with additional data such as interaction
network data and expression data will expand our under-
standing of PKMT function in cellular processes and pro-
vide novel insights into methylation signaling cascades
that are involved in human health and disease.
Methods
Protein array
Fluorescent labeling
Human protein arrays (Version 5.0; ProtoArray) were
stored at -80°C until use. Arrays were thawed on ice for 15
minutes, then blocked with 1% BSA (catalog no. A3509;
Sigma Chemical Co., St Louis, MO, USA) at room tem-
perature for 1 hour. Arrays were then incubated overnight
in a hybridization chamber (Agilent, Santa Clara, CA) with
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protocols, on a rotating tube shaker at 30°C in a reaction
mixture containing 60 μg of purified proteins (SETD7,
SETD6 and GST) and 0.1 mmol/l SAM (Sigma) in methy-
lation buffer (50 mmol/l Tris-HCl pH 8.0, 10% glycerol, 20
mmol/l KCl, 5 mmol/l MgCl2 and 1 mmol/l phenylmetha-
nesulfonyl fluoride (PMSF, Roche Applied Science, India-
napolis, IN, USA) in a total reaction volume of 500 μl).
Arrays were washed three times with PBS-T followed by
three washes with PBS-T plus 20% FCS. Arrays were then
incubated with rabbit polyclonal pan-methyl antibody
(ab23366; Abcam) for 1 hour at room temperature, fol-
lowed by incubation for 1 hour with Alexa Fluor 647
chicken anti-rabbit IgG (Invitrogen) diluted in PBS-T with
20% FCS. The arrays were washed six times with PBS-T
followed by one wash with deionized water (MilliQ; Milli-
pore, Billerica, MA, USA), then dried while shaking at
1000 rpm for 3 minutes at room temperature. Arrays were
scanned (Axon GenePix 4000B; Molecular Devices Inc.,
S u n n y v a l e ,C A ,U S A )w a su s e dt os c a nt h ea r r a y s ,a n d
data were analyzed for each block using software align-
ment (Genepix Pro 6.1 software; Molecular Devices, Sun-
nyvale, CA) and gene array list (GAL) files supplied by the
protein array manufacturer (Invitrogen).
3H-S-adenosyl-methionine labeling
The protein arrays were used as described in the fluores-
cent assay, with the following differences: blocking was
performed at 4°C; the reaction mixture used 100 to 150 μg
of PKMT enzyme and additionally contained 25 μCi
3H-
SAM and 0.5 μCi
3H-estradiol (NET517250UC; Perkin
Elmer, Waltham, MA, USA); and the reaction incubation
was performed at 22°C for 16 to 18 hours, or 37°C for
2 hours. After incubation, slides were briefly washed three
times with peptide binding buffer (50 μl Tris-HCl pH 7.5,
150 mmol/l NaCl, 0.05% NP-40), then three times with
the same buffer for 5 minutes with agitation, then briefly
three times with MilliQ water. Slides were allowed to dry,
then were exposed to radiography film (Blue Ultra Auto-
rad Film; F-9029; ISC/Bioexpress, Kaysville, UT, USA) for
1 week at -80°C. Exposed film was scanned with a scanner
(Perfection 4990 PHOTO; Epson USA, Long Beach, CA,
USA) at 16-bit grayscale and 2520 dpi under neutral con-
trast settings and saved as TIFF images. The resultant
images were cropped and rotated into the proper slide
orientation (Photoshop CS5; Adobe Systems Inc., San
J o s e ,C A ,U S A ) ,t h e ni n v e r t e dt oo b t a i nt h en e g a t i v e
image. These images were analyzed (GenePix 6.1; Molecu-
lar Devices) as in the fluorescence assay, except with man-
ual grid alignment with no spot resizing.
Data analysis
Fluorescence detection method
For the fluorescence assay, each array feature was calcu-
lated using the SNR, defined as:
((F635Mean) − (B635Mean))/(B635SD),
where (F635Mean) was the mean of all the feature pixel
intensities at 635 nm, (B635Mean)w a st h em e a no fa l l
the background pixel intensities at 635 nm, and
(B635SD) was the standard deviation of the background
pixel intensities at 635 nm.
Each protein or control was printed in duplicate as an
adjacent pair of features. For each set of experiments
(three independent experiments for GST and two arrays
for each PKMT) scanned in identical conditions (PMT =
600), the SNRs for each replicate feature pair were aver-
aged to generate an SNR value for each candidate sub-
strate. The GST SNR was subtracted from the
corresponding PKMT SNR for each candidate substrate,
and values of ≥ 3w e r ec o n s i d e r e dt ob ep o s i t i v ef o rt h a t
substrate. GST SNRs ≥ 3w e r ec o n s i d e r e dt ob en o i s e ,
and thus excluded from the dataset. Finally, all positives
hits were visually inspected, and any array features with
atypical signals (for example, single features instead of
duplicate features) were discarded from the final analysis.
Radioactive detection method
The experimental goal of the analysis of PKMT substrates
within the radioactive assay was to measure, for each spot
on the array, a robust signal, reflecting the substrate being
methylated by radiolabeled
3H-SAM. There are many
ways to accomplish this, the most obvious being to seg-
ment the image into areas (circles) corresponding to each
spot, and then determine the average signal intensity in
each circle. However, using this approach, the measure-
ment is confounded somewhat by issues involving the
compensation for the non-zero background seen on most
arrays, because the image is on film, which inherently has
background. Because not all features on the protein array
yielded a measurable
3H PKMT signal using this approach,
it was important to determine how accurately the segmen-
tation of these circular features correspond to the actual
spot locations on the array, since these are inferred from
the scanned images using the four fiducial elements as
corner markers (see Additional File 1, Figure S1). To do
so, we simulated such ‘blind’ addressing of arrayed features
using only the fiducial corner markers on the arrays,
where all features are visible as provided by the vendor
(Invitrogen), but only the corner fiducial markers are used
for gridding. Using this approach, we independently veri-
fied correct alignment in inferring the position of all
23,232 arrayed elements detectable on this platform with
no errors using these training images. Therefore, blinded
gridding of the arrays using this approach correctly identi-
fies 100% of spotted features based on their known posi-
tions, which tend to be highly reproducible within the
tolerances relevant to the current assay. Further, unlike
the pattern of noise speckles seen on the radioactive assay,
individual proteins are printed as a pair of tandem
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ine spots as PKMT targets using the radioactivity detec-
tion method, by examining scanned images of the
3H-
exposed film for pairs of adjacent spots meeting minimum
signal filtering criteria. Specifically, array features contain-
ing obvious blemishes and other artifacts were manually
flagged and omitted, with the remaining features consid-
ered if their mean net intensity (feature intensity minus
feature background) was at least 2,000 units, with mean
background not exceeding 30,000 units. Protein features
for which both adjacent replicate spots passed these cri-
teria were considered to be positive hits. Proteins with one
of two replicate features passing these criteria were consid-
ered to be positive hits if the average of the two features
passed the criteria, and if the intensity of the second repli-
cate was no more than 50% lower than that of the first
replicate. Finally, each set of experiments consisted of
three independent microarray assays, including one GST
replicate (negative control) and two replicates of each of
the on-chip enzymatic assays using the corresponding
PKMT on the protein array For SETD6, the set of positive
hits was considered to be the union of the sets of positive
hits for each of the two PKMT protein array replicates.
Peptide arrays
Peptide microarray experiments were performed as
described previously [15].
Plasmids
cDNA encoding full-length TCEA1, SRSF2, DNAJC8,
PLK1, PAK4 and RPS27L were subcloned into pGEX6P1,
and clones were confirmed by sequencing. Primers used
for cloning are shown in Table 1. For overexpression in
mammalian cells, the plasmids used were: pCAG Flag-
SETD6, pWZL Neo Myr Flag-PLK1 (plasmid 20589;
Addgene, Cambridge, MA, USA), and pWZL Neo Myr
Flag-PAK4 (Addgene plasmid 20460) [36].
In vitro lysine methylation assay
Assays were performed as previously described [37].
Briefly, recombinant proteins were incubated with recom-
binant PKMTs, and 2 mCi
3H-SAM (Amersham Pharma-
cia Biotech Inc, Piscataway, NJ, USA) in methylation
buffer (50 mmol/l Tris-HCl (pH 8.0), 10% glycerol, 20
mmol/l KCl, 5 mmol/l MgCl2 and 1 mmol/l PMSF at 30°C
overnight. The reaction mixture was resolved by SDS-
PAGE, followed by either autoradiography or Coomassie
blue stain (Pierce Protein Research/Thermo Fisher Scienti-
fic Inc., Rockford, IL, USA).
Cell lines, transfections and antibodies
Human embryonic kidney 293T cells were grown in
DMEM (Gibco/Invitrogen) supplemented with 10% FCS
(Gibco/Invitrogen), 100 U/ml penicillin and L-gluta-
mine. Cells were transfected with transfection reagent
(TransIT 293; Mirus Bio LLC, Madison, WI, USA)
according to the manufacturer’s protocols. The antibo-
dies used were anti-Flag (Sigma-Aldrich), anti-GST-HRP
(Abcam) and anti-SETD6 [14].
Additional material
Additional file 1: Figure S1 Controls present on the array for
orientation and antibody specificity. Approximately 9,500 proteins
spotted in duplicates were incubated with glutathione S-transferase (GST)
in protein lysine methyltransferase (PKMT) reaction conditions overnight
using (left) a fluorescent pan-methyl antibody and (right) radioactively
labeled S-adenosyl methionine (SAM). Boxes represent the various
controls to verify detection conditions and background using both
methods (see detailed description in text).
Additional file 2: Figure S2 Reproducibility of protein lysine
methyltransferase (PKMT) assays. (A, B) Reproducibility within a
fluorescent SET domain-containing SETD6 PKMT experiment (intra-array
concordance). Pearson correlation of net signal intensity was assessed for
pairs of replicate spots on individual microarrays, with (A) varying the
signal-to-noise ratio (SNR) and (B) at the threshold SNR = 3. (C, D)
Reproducibility between concordance of replicate measurements from
pairs of replicate microarrays (intra-array concordance) was assessed
using Pearson correlation with (C) varying the SNR and (D) at the
threshold SNR = 3. Both intra- and inter-array reproducibility measures
showed high correlation and reproducibility of measurements at SNR =
3, as measured by the corresponding correlation coefficient and P-values.
Additional file 3: Figure S3 Subcellular localization of SET domain-
containing SETD6 substrates. (A) Summary of localization data for
SETD6 and SETD7 targets, including previously validated SETD7 targets*
[11]. ‘Genes mapped’ denotes the number of PKMT substrates with Gene
Ontology (GO) cellular component annotations. These GO terms were
parsed into three broad localization categories using regular expression
definitions: nuclear (all terms capturing nucleus and subnuclear
components), extranuclear (all terms capturing cytosol, non-nuclear
organelles and secreted proteins), and nuclear and extranuclear regions.
(B, C) Pie charts showing differential localization of SETD7 and SETD6
substrates, respectively.
Table 1 Primers used for cloning.
Primer Sequence 5’®3’
TCEA-1
Forward GGCGGATCCGAGGACGAAGTGGTCCGC
Reverse GGCGAATTCTCAACAGAA CTTCCATCG
PAK4
Forward GGCGGATCCTTTGGGAAGAGGAAGAAG
Reverse GGCGAATTC TCATCTGGTGCGGTTCTG
RPS27L
Forward GGCGGATCCCCTTTGGCTAGAGATTTACTA
Reverse GGCGAATTCGAATCATTAGTGTTGCTTTCT
SRSF2
Forward GGCGGATCAGCTACGGCCGCCCC
Reverse GGCGAATTCTTAAGAGGACACCGCTCC
PLK1
Forward GGCGAATTCGCTGCAGTGACTGCAGGG
Reverse GGCGCGGCCGCTTAGGAGGCCTTGAGACG
DNAJC8
Forward GGCGGATCCGCGGCTTCAGGAGAGAGC
Reverse GGCGAATTCTCACTCACGTTGCTCCAT
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Page 10 of 12Additional file 4: Subcellular localization of SET domain-containing
SETD6 and SETD7 substrates represented in Additional file 3, Figure
S3.
Additional file 5: Substrate list for SET domain-containing SETD6
and SETD7, related to Figure 3B, Cand Figure 4A.
Additional file 6: Figure S4 Distinct Swiss-Prot gene identifiers
corresponding to the union of SETD6 candidate substrates were analyzed
for biological significance using DAVID http://david.abcc.ncifcrf.gov/[18].
For each enriched term, the number of proteins detected by each assay
(F, fluorescence; R, radioactive) are indicated by three mutually exclusive
subsets that comprise the union: ‘F Not R’, ‘R Not F’, ‘F&R ’. Enrichment
statistics were calculated based on a background population comprise all
distinct Swiss-Prot identifiers represented on the ProtoArray
®®. Only
results with a Benjamini P-value of < 0.05 are shown. For additional
details, including all enriched genes, see Additional file 7 for Gene
Ontology (GO) analysis gene list.
Additional file 7: Additional details of significantly enriched
biological annotations associated with SET domain-containing
SETD6 candidate substrates, related to Additional file 6, Figure S4.
Additional file 8: Figure S5. (A) A summary of the cloned recombinant
proteins that were used for the SET domain-containing SETD6 substrates
validation experiments. (B) Coomassie stain and (C) Western blot analysis
with anti-glutathione S-transferase (GST) antibody of recombinant
proteins used in the validation experiment (marked with asterisk) shown
in Figure 4D. Molecular size (kDa) is shown. Seq, sequence; aa, amino
acids.
List of abbreviations
BSA: bovine serum albumin; DMEM: Dulbecco’s modified Eagle’s medium;
FCS: fetal calf serum; GST: glutathione S-transferase; HEMP: human
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with Tween; PKMT: protein lysine methyltransferase; PMSF:
phenylmethanesulfonyl fluoride; SAM: S-adenosyl methionine; SDS-PAGE:
sodium dodecyl sulfate polyacrylamide gel electrophoresis; SNR: signal-to-
noise ratio.
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